BridgeBio Pharma Total Liabilities 2018-2024 | BBIO

BridgeBio Pharma total liabilities for the quarter ending December 31, 2024 were $2.377B, a 25.81% increase year-over-year.

  • BridgeBio Pharma total liabilities for 2024 were $2.377B, a 25.81% increase from 2023.
  • BridgeBio Pharma total liabilities for 2023 were $1.889B, a 1.23% increase from 2022.
  • BridgeBio Pharma total liabilities for 2022 were $1.866B, a 0.71% decline from 2021.

BridgeBio Pharma Total Liabilities 2018-2024 | BBIO

  • BridgeBio Pharma total liabilities for 2024 were $2.377B, a 25.81% increase from 2023.
  • BridgeBio Pharma total liabilities for 2023 were $1.889B, a 1.23% increase from 2022.
  • BridgeBio Pharma total liabilities for 2022 were $1.866B, a 0.71% decline from 2021.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19.4B
Dr Reddy's Laboratories (RDY)$11.2B
Bausch Health Cos (BHC)$2.4B
Supernus Pharmaceuticals (SUPN)$1.9B
Amphastar Pharmaceuticals (AMPH)$1.5B
Personalis (PSNL)$412M
Taysha Gene Therapies (TSHA)$336M
Assembly Biosciences (ASMB)$81M
Sol-Gel Technologies (SLGL)$16M
Evoke Pharma (EVOK)$8M
Teligent (TLGT)$0M